Search

Your search keyword '"de Ferranti, Sarah"' showing total 298 results
Start Over Author "de Ferranti, Sarah" Search Limiters Academic (Peer-Reviewed) Journals
298 results on '"de Ferranti, Sarah"'

3. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN

Author

Reijman, M. Doortje, Kusters, D. Meeike, Groothoff, Jaap W., Arbeiter, Klaus, Dann, Eldad J., de Boer, Lotte M., de Ferranti, Sarah D., Gallo, Antonio, Greber-Platzer, Susanne, Hartz, Jacob, Hudgins, Lisa C., Ibarretxe, Daiana, Kayikcioglu, Meral, Klingel, Reinhard, Kolovou, Genovefa D., Oh, Jun, Planken, R. Nils, Stefanutti, Claudia, Taylan, Christina, Wiegman, Albert, and Schmitt, Claus Peter

Published
2024
Full Text
View/download PDF

7. Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease

Author

Zhang, Yiyi, Dron, Jacqueline S., Bellows, Brandon K., Khera, Amit V., Liu, Junxiu, Balte, Pallavi P., Oelsner, Elizabeth C., Amr, Sami Samir, Lebo, Matthew S., Nagy, Anna, Peloso, Gina M., Natarajan, Pradeep, Rotter, Jerome I., Willer, Cristen, Boerwinkle, Eric, Ballantyne, Christie M., Lutsey, Pamela L., Fornage, Myriam, Lloyd-Jones, Donald M., Hou, Lifang, Psaty, Bruce M., Bis, Joshua C., Floyd, James S., Vasan, Ramachandran S., Heard-Costa, Nancy L., Carson, April P., Hall, Michael E., Rich, Stephen S., Guo, Xiuqing, Kazi, Dhruv S., de Ferranti, Sarah D., and Moran, Andrew E.

Published
2023
Full Text
View/download PDF

8. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050--Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association.

Author

Maddox, Karen E. Joynt, Elkind, Mitchell S. V., Aparicio, Hugo J., Commodore-Mensah, Yvonne, de Ferranti, Sarah D., Dowd, William N., Hernandez, Adrian F., Khavjou, Olga, Michos, Erin D., Palaniappan, Latha, Penko, Joanne, Poudel, Remy, Roger, Véronique L., and Kazi, Dhruv S.

Published
2024
Full Text
View/download PDF

14. Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children With Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial

Author

Altman, Carolyn A., Anderson, Brett R., Braunlin, Elizabeth, Burns, Jane C., Carr, Michael R., Choueiter, Nadine F., Colyer, Jessica H., Crean, Andrew, Dempsey, Adam, Desjardins, Laurent, Dillenburg, Rejane, Dionne, Audrey, Ferris, Anna, Gewitz, Michael, Grcic, Michelle M., Greenway, Steven C., Hamel-Perrault, Elodie, Harris, Kevin C., Hayden-Rush, Christina, Hill, Kevin D., Jain, Supriya, Jone, Pei-Ni, Kimball, Thomas R., Lang, Sean M., Li, Jennifer S., Lin, Ming-Tai, Mahle, William T., McHugh, Kimberly E., Portman, Michael A., Renaud, Claudia, Sexson Tejitel, S. Kristen, Szmuszkovicz, Jacqueline R., Texter, Karen M., Thacker, Deepika, Selamet Tierney, Elif Seda, Thomas, Thomas, Tremoulet, Adriana H., Wagner-Lees, Sharon, Warren, Andrew, Manlhiot, Cedric, Newburger, Jane W., Low, Tisiana, Dahdah, Nagib, Mackie, Andrew S., Raghuveer, Geetha, Giglia, Therese M., Dallaire, Frederic, Mathew, Mathew, Runeckles, Kyle, Pahl, Elfriede, Harahsheh, Ashraf S., Norozi, Kambiz, de Ferranti, Sarah D., Friedman, Kevin, Yetman, Anji T., Kutty, Shelby, Mondal, Tapas, and McCrindle, Brian W.

Published
2020
Full Text
View/download PDF

18. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry

Author

Luirink, Ilse K., Hutten, Barbara A., Greber-Platzer, Susanne, Kolovou, Genovefa D., Dann, Eldad J., de Ferranti, Sarah D., Taylan, Christina, Bruckert, Eric, Saheb, Samir, Oh, Jun, Driemeyer, Joenna, Farnier, Michel, Pape, Lars, Schmitt, Claus P., Novoa, Francisco J., Maeser, Martin, Masana, Luis, Shahrani, Awad, Wiegman, Albert, and Groothoff, Jaap W.

Published
2020
Full Text
View/download PDF

19. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children

Author

Lee, Pui Y., Day-Lewis, Megan, Henderson, Lauren A., Friedman, Kevin G., Lo, Jeffrey, Roberts, Jordan E., Lo, Mindy S., Platt, Craig D., Chou, Janet, Hoyt, Kacie J., Baker, Annette L., Banzon, Tina M., Chang, Margaret H., Cohen, Ezra, de Ferranti, Sarah D., Dionne, Audrey, Habiballah, Saddiq, Halyabar, Olha, Hausmann, Jonathan S., Hazen, Melissa M., Janssen, Erin, Meidan, Esra, Nelson, Ryan W., Nguyen, Alan A., Sundel, Robert P., Dedeoglu, Fatma, Nigrovic, Peter A., Newburger, Jane W., and Son, Mary Beth F.

Subjects
Immunodiagnosis -- Research, Pediatric research, Inflammation -- Diagnosis -- Complications and side effects, COVID-19 -- Diagnosis -- Complications and side effects, Pediatric multisystem inflammatory syndrome -- Diagnosis -- Complications and side effects, Health care industry
Abstract

BACKGROUND. Pediatric SARS-CoV-2 infection can be complicated by a dangerous hyperinflammatory condition termed multisystem inflammatory syndrome in children (MIS-C). The clinical and immunologic spectrum of MIS-C and its relationship to other inflammatory conditions of childhood have not been studied in detail. METHODS. We retrospectively studied confirmed cases of MIS-C at our institution from March to June 2020. The clinical characteristics, laboratory studies, and treatment response were collected. Data were compared with historic cohorts of Kawasaki disease (KD) and macrophage activation syndrome (MAS). RESULTS. Twenty-eight patients fulfilled the case definition of MIS-C. Median age at presentation was 9 years (range: 1 month to 17 years); 50% of patients had preexisting conditions. All patients had laboratory confirmation of SARS- CoV-2 infection. Seventeen patients (61%) required intensive care, including 7 patients (25%) who required inotrope support. Seven patients (25%) met criteria for complete or incomplete KD, and coronary abnormalities were found in 6 cases. Lymphopenia, thrombocytopenia, and elevation in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels were common but not ubiquitous. Cytopenias distinguished MIS-C from KD and the degree of hyperferritinemia and pattern of cytokine production differed between MIS-C and MAS. Immunomodulatory therapy given to patients with MIS-C included intravenous immune globulin (IVIG) (71%), corticosteroids (61%), and anakinra (18%). Clinical and laboratory improvement were observed in all cases, including 6 cases that did not require immunomodulatory therapy. No mortality was recorded in this cohort. CONCLUSION. MIS-C encompasses a broad phenotypic spectrum with clinical and laboratory features distinct from KD and MAS. FUNDING. This work was supported by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of Allergy and Infectious Diseases; Rheumatology Research Foundation Investigator Awards and Medical Education Award; Boston Children's Hospital Faculty Career Development Awards; the McCance Family Foundation; and the Samara Jan Turkel Center., Introduction Since the onset of the Coronavirus disease 2019 (COVID-19) pandemic, millions of individuals have been infected with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) and more than 500,000 deaths [...]

Published
2020
Full Text
View/download PDF

20. Type 1 diabetes is associated with an increase in cholesterol absorption markers but a decrease in cholesterol synthesis markers in a young adult population

Author

Semova, Ivana, Levenson, Amy E., Krawczyk, Joanna, Bullock, Kevin, Williams, Kathryn A., Wadwa, R. Paul, Shah, Amy S., Khoury, Philip R., Kimball, Thomas R., Urbina, Elaine M., de Ferranti, Sarah D., Bishop, Franziska K., Maahs, David M., Dolan, Lawrence M., Clish, Clary B., and Biddinger, Sudha B.

Published
2019
Full Text
View/download PDF

22. Associations of Blood Pressure and Cholesterol Levels During Young Adulthood With Later Cardiovascular Events

Author

Zhang, Yiyi, Vittinghoff, Eric, Pletcher, Mark J., Allen, Norrina B., Zeki Al Hazzouri, Adina, Yaffe, Kristine, Balte, Pallavi P., Alonso, Alvaro, Newman, Anne B., Ives, Diane G., Rana, Jamal S., Lloyd-Jones, Donald, Vasan, Ramachandran S., Bibbins-Domingo, Kirsten, Gooding, Holly C., de Ferranti, Sarah D., Oelsner, Elizabeth C., and Moran, Andrew E.

Published
2019
Full Text
View/download PDF

23. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Author

Grundy, Scott M., Stone, Neil J., Bailey, Alison L., Beam, Craig, Birtcher, Kim K., Blumenthal, Roger S., Braun, Lynne T., de Ferranti, Sarah, Faiella-Tommasino, Joseph, Forman, Daniel E., Goldberg, Ronald, Heidenreich, Paul A., Hlatky, Mark A., Jones, Daniel W., Lloyd-Jones, Donald, Lopez-Pajares, Nuria, Ndumele, Chiadi E., Orringer, Carl E., Peralta, Carmen A., Saseen, Joseph J., Smith, Sidney C., Jr., Sperling, Laurence, Virani, Salim S., and Yeboah, Joseph

Published
2019
Full Text
View/download PDF

24. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Author

Grundy, Scott M., Stone, Neil J., Bailey, Alison L., Beam, Craig, Birtcher, Kim K., Blumenthal, Roger S., Braun, Lynne T., de Ferranti, Sarah, Faiella-Tommasino, Joseph, Forman, Daniel E., Goldberg, Ronald, Heidenreich, Paul A., Hlatky, Mark A., Jones, Daniel W., Lloyd-Jones, Donald, Lopez-Pajares, Nuria, Ndumele, Chiadi E., Orringer, Carl E., Peralta, Carmen A., Saseen, Joseph J., Smith, Sidney C., Jr., Sperling, Laurence, Virani, Salim S., and Yeboah, Joseph

Published
2019
Full Text
View/download PDF

27. Elevation of IL-17 Cytokines Distinguishes Kawasaki Disease From Other Pediatric Inflammatory Disorders.

Author

Brodeur, Kailey E., Meng Liu, Ibanez, Daniel, de Groot, Mareike J., Liang Chen, Yan Du, Seyal, Eman, Laza-Briviesca, Raquel, Baker, Annette, Chang, Joyce C., Chang, Margaret H., Day-Lewis, Megan, Dedeoglu, Fatma, Dionne, Audrey, de Ferranti, Sarah D., Friedman, Kevin G., Halyabar, Olha, Lo, Mindy S., Meidan, Esra, and Sundel, Robert P.

Subjects
INTERLEUKINS, CYTOKINES, BIOMARKERS, MULTISYSTEM inflammatory syndrome, MACROPHAGE activation syndrome, DERMATOMYOSITIS, CONFIDENCE intervals, RESEARCH funding, MUCOCUTANEOUS lymph node syndrome, ARTHRITIS, RECEIVER operating characteristic curves, CHILDREN
Abstract

Objective. Kawasaki disease (KD) is a systemic vasculitis of young children that can lead to development of coronary artery aneurysms. We aimed to identify diagnostic markers to distinguish KD from other pediatric inflammatory diseases. Methods. We used the proximity extension assay to profile proinflammatory mediators in plasma samples from healthy pediatric controls (n = 30), febrile controls (n = 26), and patients with KD (n = 23), multisystem inflammatory syndrome in children (MIS-C; n = 25), macrophage activation syndrome (n = 13), systemic and nonsystemic juvenile idiopathic arthritis (n = 14 and n = 10, respectively), and juvenile dermatomyositis (n = 9). We validated the key findings using serum samples from additional patients with KD (n = 37) and febrile controls (n = 28). Results. High-fidelity proteomic profiling revealed distinct patterns of cytokine and chemokine expression across pediatric inflammatory diseases. Although KD and MIS-C exhibited many similarities, KD differed from MIS-C and other febrile diseases in that most patients exhibited elevation in one or more members of the interleukin-17 (IL-17) cytokine family, IL-17A, IL-17C, and IL-17F. IL-17A was particularly sensitive and specific, discriminating KD from febrile controls with an area under the receiver operator characteristic curve of 0.95 (95% confidence interval 0.89–1.00) in the derivation set and 0.91 (0.85–0.98) in the validation set. Elevation of all three IL-17-family cytokines was observed in over 50% of KD patients, including 19 of 20 with coronary artery aneurysms, but was rare in all other comparator groups. Conclusion. Elevation of IL-17 family cytokines is a hallmark of KD and may help distinguish KD from its clinical mimics. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel

Author

Sturm, Amy C., Knowles, Joshua W., Gidding, Samuel S., Ahmad, Zahid S., Ahmed, Catherine D., Ballantyne, Christie M., Baum, Seth J., Bourbon, Mafalda, Carrié, Alain, Cuchel, Marina, de Ferranti, Sarah D., Defesche, Joep C., Freiberger, Tomas, Hershberger, Ray E., Hovingh, G. Kees, Karayan, Lala, Kastelein, Johannes Jacob Pieter, Kindt, Iris, Lane, Stacey R., Leigh, Sarah E., Linton, MacRae F., Mata, Pedro, Neal, William A., Nordestgaard, Børge G., Santos, Raul D., Harada-Shiba, Mariko, Sijbrands, Eric J., Stitziel, Nathan O., Yamashita, Shizuya, Wilemon, Katherine A., Ledbetter, David H., and Rader, Daniel J.

Published
2018
Full Text
View/download PDF

34. Kawasaki disease and immunisation: A systematic review

Author

Phuong, Linny Kimly, Bonetto, Caterina, Buttery, Jim, Pernus, Yolanda Brauchli, Chandler, Rebecca, Felicetti, Patrizia, Goldenthal, Karen L., Kucuku, Merita, Monaco, Giuseppe, Pahud, Barbara, Shulman, Stanford T., Top, Karina A., Trotta, Francesco, Ulloa-Gutierrez, Rolando, Varricchio, Frederick, de Ferranti, Sarah, Newburger, Jane W., Dahdah, Nagib, Singh, Surjit, Bonhoeffer, Jan, and Burgner, David

Published
2017
Full Text
View/download PDF

36. Kawasaki disease and immunisation: Standardised case definition & guidelines for data collection, analysis

Author

Phuong, Linny Kimly, Bonetto, Caterina, Buttery, Jim, Pernus, Yolanda Brauchli, Chandler, Rebecca, Goldenthal, Karen L., Kucuku, Merita, Monaco, Giuseppe, Pahud, Barbara, Shulman, Stanford T., Top, Karina A., Ulloa-Gutierrez, Rolando, Varricchio, Frederick, de Ferranti, Sarah, Newburger, Jane W., Dahdah, Nagib, Singh, Surjit, Bonhoeffer, Jan, and Burgner, David

Published
2016
Full Text
View/download PDF

45. MIS-C across three SARS-CoV-2 variants: Changes in COVID-19 testing and clinical characteristics in a cohort of U.S. children.

Author

Laird-Gion, Jessica, Dionne, Audrey, Gauvreau, Kimberlee, Baker, Annette, Day-Lewis, Megan, de Ferranti, Sarah, Friedman, Kevin, Khan, Numaira, Mahanta, Simran, Son, Mary Beth, Sperotto, Francesca, and Newburger, Jane W.

Subjects
MULTISYSTEM inflammatory syndrome in children, SARS-CoV-2, SARS-CoV-2 Omicron variant, COVID-19 testing, LYMPHOCYTE count
Abstract

As new variants of SARS-Co-V 2 have emerged over time and Omicron sub-variants have become dominant, the severity of illness from COVID-19 has declined despite greater transmissibility. There are fewer data on how the history, diagnosis, and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) have changed with evolution in SARS-CoV-2 variants. We conducted a retrospective cohort study of patients hospitalized with MIS-C between April 2020 and July 2022 in a tertiary referral center. Patients were sorted into Alpha, Delta, and Omicron variant cohorts by date of admission and using national and regional data on variant prevalence. Among 108 patients with MIS-C, significantly more patients had a documented history of COVID-19 in the two months before MIS-C during Omicron (74%) than during Alpha (42%) (p = 0.03). Platelet count and absolute lymphocyte count were lowest during Omicron, without significant differences in other laboratory tests. However, markers of clinical severity, including percentage with ICU admission, length of ICU stay, use of inotropes, or left ventricular dysfunction, did not differ across variants. This study is limited by its small, single‐center case series design and by classification of patients into era of variant by admission date rather than genomic testing of SARS‐ CoV‐2 samples. Conclusion: Antecedent COVID-19 was more often documented in the Omicron than Alpha or Delta eras, but clinical severity of MIS-C was similar across variant eras. What is Known: • There has been a decrease in incidence of MIS-C in children despite widespread infection with new variants of COVID-19. • Data has varied on if the severity of MIS-C has changed over time across different variant infections. What is New: • MIS-C patients were significantly more likely to report a known prior infection with SARS-CoV-2 during Omicron than during Alpha. • There was no difference in severity of MIS-C between the Alpha, Delta, and Omicron cohorts in our patient population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry.

Author

Cuchel, Marina, Lee, Paul C., Hudgins, Lisa C., Duell, P. Barton, Ahmad, Zahid, Baum, Seth J., Linton, MacRae F., de Ferranti, Sarah D., Ballantyne, Christie M., Larry, John A., Hemphill, Linda C., Kindt, Iris, Gidding, Samuel S., Martin, Seth S., Moriarty, Patrick M., Thompson, Paul P., Underberg, James A., Guyton, John R., Andersen, Rolf L., and Whellan, David J.

Published
2023
Full Text
View/download PDF

48. Vascular Health in Kawasaki Disease

Author

Selamet Tierney, Elif Seda, Gal, Dana, Gauvreau, Kimberly, Baker, Annette L., Trevey, Shari, O'Neill, Stephen R., Jaff, Michael R., de Ferranti, Sarah, Fulton, David R., Colan, Steven D., and Newburger, Jane W.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results